Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on Southwest Oncology Group protocol s8897.

Publication Type:

Journal Article


Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Volume 26, Issue 8, p.1223-30 (2008)


2008, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Chemotherapy, Adjuvant, Cyclophosphamide, Dose-Response Relationship, Drug, Doxorubicin, Female, Fluorouracil, Heart, Heart Failure, Humans, methotrexate, Middle Aged, Prognosis, Public Health Sciences Division, Receptor, erbB-2, Survival Rate, Survivors, Tamoxifen, Ventricular Dysfunction, Left


The late cardiac effects of adjuvant anthracycline therapy in survivors of early-stage breast cancer have had limited study. Subclinical and clinical cardiac late effects may contribute to added comorbidity over time.